Lonza | GenomeWeb

Lonza

NEW YORK (GenomeWeb News) – Precision BioSciences said today that it is suing Lonza Group and a number of its affiliates for patent infringement.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Becton Dickinson announced the latest round of winners of its BD Biosciences Research Grant Program. Winners will receive $10,000 worth of research reagents for their projects.

Lonza now offers kits and services featuring Roche's MycoTool detection kits for final release testing of pharmaceutical products, upon validation. In the meantime, Lonza continues to develop its own pharma QC products, including mycoplasma detection assays, on BD's automated testing platform.

The MycoTool PCR-based test is the first commercial nucleic acid testing-based detection system for mycoplasma biosafety testing of approved biological products.

BD Diagnostics and Switzerland's Lonza have inked an agreement to develop and commercialize Lonza's microCompass molecular assays on the BD Max system for pharmaceutical quality-control testing.

Lonza's microCompass assays will facilitate rapid detection for total bioburden load, sterility testing, Mycoplasma, and other specific organisms, the two firms said.

BHB, founded in 2006, is betting that the new service offering will generate both new revenues and additional sales of its StellARray and XenoQ plate-based PCR kits.

Lonza is distributing Bar Harbor BioTechnology's new tools under an exclusive agreement.

Product Watch

Premium

Bar Harbor's XenoQ assays

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.